Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. - Yarnoff B; Beuvelet M; Soudani S; Neary MP; Hodges EN; Chit A; Tribaldos M; Gabriel V; Musci R; Geurtsen J; Krilov LR (Infectious diseases and therapy, 2026)